Celltrion completes clinical trials for Remsima SC for European approval

Published: 2018-08-31 16:29:00
Updated: 2018-09-03 15:53:02

Celltrion completed a Phase III clinical trial to get approval of ‘Remsima SC(CT-P13 SC),’ a subcutaneous injection version of the antibody biosimilar for the treatment of autoimmune therapy ‘Remsima(generic name: infliximab),’ announced that they were about to finish the approval process for Eur...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.